Mishalian Inbal, Granot Zvi, Fridlender Zvi G
Institute of Pulmonary Medicine, Hadassah-Hebrew University Medical Center, POB 12000, Jerusalem 91120, Israel.
The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel.
Immunobiology. 2017 Jan;222(1):82-88. doi: 10.1016/j.imbio.2016.02.001. Epub 2016 Feb 3.
Neutrophils, the most abundant leukocyte in human circulation are being more and more recognized as part of the immune reaction to cancer. In the last years, the understanding that neutrophils possess a dual role in cancer development has emerged. During tumor progression the number of neutrophils increase, and their phenotype change. In advanced cancer, we can find several sub-populations of circulating neutrophils possessing different characteristics of maturity, tumor cytotoxicity and immune suppression. One important sub-population of circulating neutrophils is the granulocytic myeloid derived suppressor cells (G-MDSC). Differencing G-MDSC from other sub-populations of neutrophils in the circulation is a complex and controversial task, as there are no clear definitions of the differences between these granulocytic sub-populations. Herein we review the differences described thus far between G-MDSC and other circulating neutrophils. We then compare the morphology, surface markers, function and prognostic importance of the different tumor-related circulating neutrophils, as described by us and others, and discuss the possible relations between the different sub-populations, their source and fate. Lastly, we suggest a nomenclature to try and encompass the full range of circulating neutrophils in cancer.
中性粒细胞是人体循环中最丰富的白细胞，越来越被认为是癌症免疫反应的一部分。在过去几年中，人们逐渐认识到中性粒细胞在癌症发展中具有双重作用。在肿瘤进展过程中，中性粒细胞数量增加，其表型也会发生变化。在晚期癌症中，我们可以发现循环中性粒细胞的几个亚群，它们具有不同的成熟度、肿瘤细胞毒性和免疫抑制特征。循环中性粒细胞的一个重要亚群是粒细胞性髓系来源抑制细胞（G-MDSC）。区分循环中的G-MDSC与其他中性粒细胞亚群是一项复杂且有争议的任务，因为这些粒细胞亚群之间差异的定义并不明确。在此，我们回顾了迄今为止所描述的G-MDSC与其他循环中性粒细胞之间的差异。然后，我们比较了我们和其他人所描述的不同肿瘤相关循环中性粒细胞的形态、表面标志物、功能和预后重要性，并讨论了不同亚群之间可能的关系、它们的来源和归宿。最后，我们提出一种命名法，试图涵盖癌症中循环中性粒细胞的全部范围。
